FOXO3

Foxo3

VITAFOXO

Back Pain

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan.

Description

Team

0x3ffab…19bbb

Owner

Organisation

University of Exeter

Experiment Cost

$150,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Foxo3

VITAFOXO

Back Pain

Description

Team

0x3ffab…19bbb

Owner

Organisation

University of Exeter

Experiment Cost

$150,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project explicitly states that no experimental work has been conducted and no experimental results have been generated. The project is at the AON design stage (pre-clinical discovery phase), with all supporting evidence derived exclusively from published literature by the PI and others, not from this specific project. The proposal describes detailed experimental plans (Milestones 1a, 1b, 2) but none have produced data yet, placing this squarely at TRL 1 — concept alone with theoretical and literature-based support.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.90

Overall Assessment

The FOXO3 AON project scores a solid 3.90 out of 5.00, reflecting a scientifically compelling TRL 1 concept with notable strengths and identifiable risks. The strongest dimension is therapeutic optionality (5/5), as FOXO3 represents a master regulatory node with validated relevance across multiple major disease categories totaling over $600B in combined market opportunity. Therapeutic relevance scores well (4/5) due to strong genetic validation of FOXO3 in human longevity, published mechanistic links to the lead indication (DDD), and the use of a clinically proven modality (steric hindrance ASOs). The main limitation is that all evidence is literature-derived with no project-specific experimental data yet generated. Intellectual property is the weakest dimension (3/5) — while the concept is novel and the FTO landscape appears favorable, no patents exist yet, and the IP strategy depends entirely on successful Phase 1 execution. The project benefits from an experienced PI with deep oligonucleotide expertise (30 years, SENISCA founder/CSO, 160+ publications) and a well-structured experimental plan with clear go/no-go criteria. Key risks to monitor include: the absence of any experimental validation to date, dependence on a PDRA yet to be appointed, the need to generate patentable data before competitors enter the FOXO3 isoform space, and the contingent nature of Phase 2 funding for in vivo validation. Overall, this is an above-average TRL 1 project with a strong scientific foundation and exceptional breadth of potential, appropriately de-risked by a staged funding structure with intermediate go/no-go milestones.

Weighted Score

Therapeutic Relevance

The proposed mechanism is scientifically plausible and well-supported. FOXO3 is a genetically validated longevity target with the rs2802292 G-allele associated with ~36% increased exceptional longevity across >11 human populations. Published evidence directly links FOXO3 to DDD: FOXO3 expression correlates with DDD in mouse and human, and FOXO3 overexpression ameliorates IVD degeneration by decreasing NLRP3-mediated pyroptosis. The isoform-specific AON approach (shifting FOXO3-long/short balance) is mechanistically coherent — aging tilts the balance toward the truncated short form, and restoring the long form activates autophagy, mitochondrial quality control, DNA repair, and anti-inflammatory signaling. The AON modality is clinically validated (4 FDA approvals in 2023 alone for steric hindrance ASOs). However, a score of 5 is not warranted because: (1) no experimental data yet exists for this specific project — all evidence is from published literature and the PI's prior work at SENISCA, not from FOXO3-specific AONs; (2) the causal chain from isoform ratio modulation to disease modification in DDD remains hypothetical and unvalidated; (3) FOXO3 has never been successfully pharmacologically targeted, which while representing novelty also represents risk. The biological rationale is strong but entirely pre-experimental at this stage.

Therapeutic Optionality

Therapeutic optionality is exceptional. FOXO3 is described as a 'central node' orchestrating multiple downstream pathways (autophagy, mitochondrial maintenance, DNA-damage repair, metabolic flexibility, inflammatory restraint) that are relevant across virtually all major age-related disease categories. The proposal explicitly identifies seven therapeutic areas beyond DDD: cardiovascular disease ($160B market), cancer ($200B), autoimmune/immune dysfunction ($170B), diabetes ($40B), neurodegeneration ($20B), sarcopenia ($4B), and the primary DDD indication ($35B). The AON platform approach is inherently flexible — the same antisense strategy can be retargeted systemically or to other organs. The concept of modulating an evolutionarily conserved hub rather than a single downstream pathology provides genuine breadth. The flexibility of the oligonucleotide modality (can enhance or repress, can be delivered locally or systemically with different formulations) further enhances optionality. This earns the maximum score as few TRL 1 concepts offer this breadth of potential application across such large disease markets.

Intellectual Property

The concept is novel enough for patenting — FOXO3 has never been successfully pharmacologically targeted, and the isoform-specific ASO approach is distinct from prior art (previous agonists like trehalose had pleiotropic, non-specific effects). The planned IP scope is comprehensive: composition of matter for ASOs targeting FOXO3 isoform-specific sequences, methods of use for modulating isoform ratios, methods of treating DDD and other FOXO3-associated conditions, and optimized chemistries/formulations. The FTO position appears strong given the novelty of the approach. However, significant weaknesses temper the score: (1) No patents have been filed yet — IP is entirely 'to be generated' from Phase 1 data; (2) The PI has 2 issued patents and 7 in draft through SENISCA, raising potential questions about overlap or freedom-to-operate relative to SENISCA's existing oligonucleotide portfolio, though the FOXO3 target appears distinct; (3) Patent claims based solely on 2D/3D culture data (Phase 1 output) may be narrow and vulnerable without in vivo validation, which is contingent on Phase 2 funding; (4) The 12-month window to bolster claims with in vivo data post-filing introduces execution risk. The concept is patentable but the IP position is currently aspirational rather than established.